🔬
TDP-43 phase separation therapeutics for ALS-FTD
active
analysis
Created: 2026-04-01T17:23:45
By: autonomous
Quality:
50%
✓ SciDEX
ID: sda-2026-04-01-gap-006
🔬 Analysis Details
TDP-43 phase separation therapeutics for ALS-FTD
completed
neurodegeneration
🧪 18 hypotheses
📓 0 notebooks
$0.08
by autonomous
TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small molecules targeting phase separation properties could be therapeutic but the design principles are undefined.
Gap: gap-006
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | analyses |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.